References
- Siegel RL, Miller KD, Jemal A. 2015. Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. doi:10.3322/caac.21254.
- Pourmand K, Itzkowitz SH. 2016. Small bowel neoplasms and polyps. Curr Gastroenterol Rep. 18:23. doi:10.1007/s11894-016-0497-x.
- Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. 2010. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 199:797–803. doi:10.1016/j.amjsurg.2009.05.037.
- Pan SY, Morrison H. 2011. Epidemiology of cancer of the small intestine. World J Gastrointest Oncol. 3:33–42. doi:10.4251/wjgo.v3.i3.33.
- Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. 2004. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 101:518–526. doi:10.1002/cncr.20404.
- Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med. 358:2039–2049. doi:10.1056/NEJMra0706596.
- Dvorak HF. 2002. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol. 20:4368–4380. doi:10.1200/JCO.2002.10.088.
- Tampellini M, Sonetto C, Scagliotti GV. 2016. Novel anti-angiogenic therapeutic strategies in colorectal cancer. Expert Opin Investig Drugs. 25:507–520. doi:10.1517/13543784.2016.1161754.
- Sun Q, Zhou J, Zhang Z, Guo M, Liang J, Zhou F, Long J, Zhang W, Yin F, Cai H, et al. 2014. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy. Cancer Biol Ther. 15:1635–1645. doi:10.4161/15384047.2014.964087.
- Xu RH, Li J, Bai Y, Xu J, Liu T, Shen L, Wang L, Pan H, Cao J, Zhang D, et al. 2017. Safety and efficacy of fruquintinib in patients with previously treated metastatic colorectal cancer: a phase Ib study and a randomized double-blind phase II study. J Hematol Oncol. 10:22. doi:10.1186/s13045-016-0384-9.
- Li J, Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, et al. 2018. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial. JAMA. 319:2486–2496. doi:10.1001/jama.2018.7855.
- Tian S, Quan H, Xie C, Guo H, Lu F, Xu Y, Li J, Lou L. 2011. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 102:1374–1380. doi:10.1111/j.1349-7006.2011.01939.x.
- Chen X, Qiu T, Zhu Y, Sun J, Li P, Wang B, Lin P, Cai X, Han X, Zhao F, et al. 2019. A single-arm, phase II study of apatinib in refractory metastatic colorectal cancer. Oncologist. doi: 10.1634/theoncologist.2019-0164.
- Wang FWS, Yuan X, Jia J, Bi X, Zhou Z, Zhou Q, Luo C, Deng M, Yi L, Li Y. 2019. Apatinib monotherapy for chemotherapy-refractory metastatic colorectal cancer: A multicenter, single-arm, prospective study. J Clin Oncol. 37: 3527-3527. doi:10.1200/JCO.2019.37.15_suppl.3527.
- Fan F, Wey JS, McCarty MF, Belcheva A, Liu W, Bauer TW, Somcio RJ, Wu Y, Hooper A, Hicklin DJ, et al. 2005. Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells. Oncogene. 24:2647–2653. doi:10.1038/sj.onc.1208246.
- Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res. 1995;55:3964–3968.
- Jayson GC, Kerbel R, Ellis LM, Harris AL. 2016. Antiangiogenic therapy in oncology: current status and future directions. Lancet. 388:518–529. doi:10.1016/S0140-6736(15)01088-0.
- Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. 2013. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 10:643–655. doi:10.1038/nrclinonc.2013.170.
- Procaccio L, Damuzzo V, Di Sarra F, Russi A, Todino F, Dadduzio V, Bergamo F, Prete AA, Lonardi S, Prenen H, et al. 2019. Safety and tolerability of anti-angiogenic protein kinase inhibitors and vascular-disrupting agents in cancer: focus on gastrointestinal malignancies. Drug Saf. 42:159–179. doi:10.1007/s40264-018-0776-6.
- Jeong JH, Kim J, Hong YS, Kim D, Kim JE, Kim SY, Kim KP, Yoon YK, Kim D, Chun SM, et al. 2017. HER2 amplification and cetuximab efficacy in patients with metastatic colorectal cancer harboring wild-type RAS and BRAF. Clin Colorectal Cancer. 16:e147–e152. doi:10.1016/j.clcc.2017.01.005.